Greenwood Capital Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.97M | Sell |
12,024
-77
| -0.6% | -$34.1K | 0.59% | 62 |
|
|
2026
Q1 | $5.4M | Sell |
12,101
-221
| -2% | -$103K | 0.6% | 55 |
|
|
2025
Q4 | $5.59M | Sell |
12,322
-490
| -4% | -$211K | 0.61% | 55 |
|
|
2025
Q3 | $5.02M | Buy |
12,812
+2,514
| +24% | +$1.05M | 0.58% | 59 |
|
|
2025
Q2 | $4.58M | Sell |
10,298
-1,595
| -13% | -$735K | 0.57% | 61 |
|
|
2025
Q1 | $5.77M | Sell |
11,893
-6,572
| -36% | -$3.06M | 0.78% | 41 |
|
|
2024
Q4 | $7.44M | Sell |
18,465
-2,059
| -10% | -$954K | 0.97% | 33 |
|
|
2024
Q3 | $9.55M | Sell |
20,524
-669
| -3% | -$321K | 1.24% | 16 |
|
|
2024
Q2 | $9.93M | Buy |
21,193
+1,058
| +5% | +$459K | 1.31% | 16 |
|
|
2024
Q1 | $8.42M | Sell |
20,135
-5,210
| -21% | -$2.2M | 1.12% | 24 |
|
|
2023
Q4 | $10.3M | Buy |
25,345
+2,576
| +11% | +$952K | 1.34% | 13 |
|
|
2023
Q3 | $7.92M | Sell |
22,769
-5,429
| -19% | -$1.9M | 1.15% | 24 |
|
|
2023
Q2 | $9.92M | Sell |
28,198
-315
| -1% | -$106K | 1.39% | 14 |
|
|
2023
Q1 | $8.98M | Buy |
28,513
+370
| +1% | +$111K | 1.29% | 20 |
|
|
2022
Q4 | $8.13M | Sell |
28,143
-2,276
| -7% | -$694K | 1.33% | 27 |
|
|
2022
Q3 | $8.81M | Sell |
30,419
-774
| -2% | -$223K | 1.51% | 15 |
|
|
2022
Q2 | $8.79M | Buy |
31,193
+30,938
| +12,133% | +$8.28M | 1.41% | 21 |
|
|
2022
Q1 | $67K | Sell |
255
-55,061
| -100% | -$13.1M | 0.02% | 166 |
|
|
2021
Q4 | $12.1M | Sell |
55,316
-232
| -0.4% | -$45.1K | 1.72% | 13 |
|
|
2021
Q3 | $10.1M | Buy |
55,548
+6,219
| +13% | +$1.21M | 1.55% | 16 |
|
|
2021
Q2 | $9.95M | Buy |
49,329
+27,202
| +123% | +$5.69M | 1.5% | 19 |
|
|
2021
Q1 | $4.75M | Buy |
22,127
+2,298
| +12% | +$505K | 0.75% | 43 |
|
|
2020
Q4 | $4.69M | Buy |
+19,829
| New | +$4.55M | 0.79% | 45 |
|
|
2017
Q3 | – | Sell |
-1,897
| Closed | -$244K | – | 226 |
|
|
2017
Q2 | $244K | Buy |
+1,897
| New | +$228K | 0.06% | 156 |
|
|
2016
Q1 | – | Sell |
-10,768
| Closed | -$1.35M | – | 179 |
|
|
2015
Q4 | $1.35M | Buy |
10,768
+80
| +0.7% | +$9.66K | 0.44% | 77 |
|
|
2015
Q3 | $1.11M | Sell |
10,688
-11,032
| -51% | -$1.42M | 0.39% | 71 |
|
|
2015
Q2 | $2.68M | Sell |
21,720
-892
| -4% | -$112K | 0.81% | 52 |
|
|
2015
Q1 | $2.67M | Sell |
22,612
-23,930
| -51% | -$2.87M | 0.76% | 60 |
|
|
2014
Q4 | $5.53M | Buy |
46,542
+5,038
| +12% | +$567K | 1.6% | 16 |
|
|
2014
Q3 | $4.66M | Buy |
+41,504
| New | +$3.95M | 1.43% | 21 |
|
|
2013
Q4 | – | Sell |
-2,845
| Closed | -$216K | – | 115 |
|
|
2013
Q3 | $216K | Buy |
+2,845
| New | +$226K | 0.08% | 98 |
|
Other funds holding VRTX
DC
BHIA
Greenwood Capital Associates's VRTX Position: Q2 2026 in Review
Greenwood Capital Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 0.64% in Q2 2026, selling an estimated $34.1K and leaving 12,024 shares worth $5.97M. The position accounts for 0.59% of the portfolio, ranked #62.
Greenwood Capital Associates first reported a position in VRTX in Q3 2013 and has held it in 31 quarters since. The position peaked at $12.1M in Q4 2021. 597 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Greenwood Capital Associates held 12,024 shares of Vertex Pharmaceuticals worth $5.97M as of Q2 2026.
- Greenwood Capital Associates sold 77 Vertex Pharmaceuticals shares in Q2 2026, an estimated $34.1K.
- Vertex Pharmaceuticals made up 0.59% of Greenwood Capital Associates's portfolio in Q2 2026, its #62 holding.
- Greenwood Capital Associates first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 31 quarters since.
- Greenwood Capital Associates's Vertex Pharmaceuticals position peaked at $12.1M in Q4 2021.
- 597 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.